During the past decade, considerable scientific, clinical, andpublic interest in the benefits and risks of postmenopausalestrogen therapy has focused attention on selective estrogen-receptormodulators (SERMs). These act as estrogen agonists in some tissuesand antagonists in others because of specific actions on atleast two distinct estrogen receptors, the proportions of whichdiffer across tissues. As such, SERMs have held the promiseof conferring benefits similar to those associated with estrogentherapy, including a reduced risk of osteoporosis, while simultaneouslyreducing estrogen-related risks (e.g., invasive breast cancer).The once widely held belief that estrogen therapy was cardioprotective1also . . . [Full Text of this Article]
Source Information
From the Stanford Prevention Research Center, Stanford School of Medicine, Stanford, Calif.
This article has been cited by other articles:
Mosca, L., Grady, D., Barrett-Connor, E., Collins, P., Wenger, N., Abramson, B. L., Paganini-Hill, A., Geiger, M. J., Dowsett, S. A., Amewou-Atisso, M., Kornitzer, M.
(2009). Effect of Raloxifene on Stroke and Venous Thromboembolism According to Subgroups in Postmenopausal Women at Increased Risk of Coronary Heart Disease. Stroke
40: 147-155
[Abstract][Full Text]
(2006). Raloxifene Does Not Prevent Heart Disease. Journal Watch Cardiology
2006: 2-2
[Full Text]
(2006). Raloxifene and Risk for Cardiovascular Events and Breast Cancer. JWatch Women's Health
2006: 1-1
[Full Text]
(2006). Outcomes with Raloxifene in Women with Above-Average Coronary Risk. JWatch General
2006: 1-1
[Full Text]
Previous
